Alex Friedlaender

Enjoying oncology, without meaning to sound too cynical

[UroToday.com @urotoday]

Are there patients with PSA recurrence who do not need imaging and treatment? Presentation by @DrSpratticus @UHhospitals. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/qiV0LhGO7l @APCCC_Lugano

[NEJM @NEJM]

Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: https://t.co/sKJ6Sr6WiW

[Alex Friedlaender @DralexGva]

@DrYukselUrun @TheLancet @myESMO @IASLC @OncoAlert @DrJNaidoo @JackWestMD @yekeduz_emre @gbanna74 @StephenVLiu @peters_solange @jsoriamd @CharuAggarwalMD @RamalingamMD @PatelOncology A big question is durable response. With IO we have been abke to stop treatment and maintain "remission". Will Ivonescimab be able to do the same?

[Alex Friedlaender @DralexGva]

@gbanna74 Now we need to see how a bladder sparing approach can be studied in this setting!
Duration of neoadjuvant therapy could also come into play.

[Alex Friedlaender @DralexGva]

@PBlanchardMD Another question is whether prolonging neoadjuvant therapy could increase pCR and offer potential bladder preservation approaches to more patients. Trials are needed to address the implications of EV-P in such approaches.
Bladder preservation would justify the cost/tox.

[Alex Friedlaender @DralexGva]

@gbanna74 @NEJM @OncoAlert @FordePatrick @MARIANOPROVENCI @DoctorJSpicer Very reassuring and for many of us, practice-confirming for the choice of this regimen. Thanks for sharing!

[Alex Friedlaender @DralexGva]

@EiocOncology @StephenVLiu @OncoAlert @ASCO @ASCOPost @myESMO @Larvol @oncodaily @OncBrothers The no crossover allowed part is probably limiting in a lot of countries where options are very limited... I wonder what would happen with the 3m most benefit with crossover.

[Alex Friedlaender @DralexGva]

@MikeSerzanMD @TiansterZhang I am surprised by the fact that the control arm didn't have the option of a docetaxel triplet as in PEACE-1. Not sure how many of us would treat BRCA mHSPC (especially high V) with abi alone. Not me...
Also for OS analysis, do we have the % of subsequent PARPi use in control arm?

[Alex Friedlaender @DralexGva]

@ACortelliniMD @jitcancer @myESMO @CampusBioMedico @ImperialSandC Amazing work, Alessio! Thank you!

[Alex Friedlaender @DralexGva]

Among molecularly selected patients with mCRPC, ipi 1/nivo 3 has 81% DCR in mmr, 25% in TMBh, 15-19% in CDK12i and BRCA...
#ESMO2024 @MehraNiven

[Alex Friedlaender @DralexGva]

AR degrader in multi-treated CRPC may offer a new treatment option! #ESMO2024

[Alex Friedlaender @DralexGva]

Stampede arm K: exploratory analysis: possible OS benefit in high Volume group (unpowered).
Interestingly, less weight gain with metformin! #ESMO24

[Alex Friedlaender @DralexGva]

Transdermal estrogen vs ADT seem equivalent in efficacy for hormone sensitive prostate cancer. Different tox profile (lower hot flashes, no bone tox, but higher gynecomastia).

[Alex Friedlaender @DralexGva]

@tompowles1 presents positive data for Niagara in muscle invasive bladder cancer. Of course, access to IO in the control arm upon progression would be interesting to see...
Similarly, is this superior to adjuvant only?

[Alex Friedlaender @DralexGva]

@Tony_Calles proposes a risk based stratification to investigate treatment efficacy in early NSCLC #ESMO2024

[Alex Friedlaender @DralexGva]

@Tony_Calles reminds us that the FDA will be strict about trial design to ascertain the value of each part (no vs adjuvant) of therapy in NSCLC moving forward. #ESMO2024

[Alex Friedlaender @DralexGva]

Non metastatic NSCLC management has come a long way in the last 5 years. Still a lot of work to do to tailor therapeutic choices... #ESMO2024

[Alex Friedlaender @DralexGva]

Post surgical ctDNA clearance is associated with improved EFS in localized NSCLC in AEGEAN, as presented by Martin Reck @myESMO #ESMO2024
Will ctDNA make its way into routine care?

[Alex Friedlaender @DralexGva]

@Tony_Calles I think seeing a survival plateau will be an important factor to consider (in addition to the international trial).

[Alex Friedlaender @DralexGva]

@ManniMD1 It is mind-boggling that your comment isn't obvious to physicians and industry alike...